07/17/2018
https://congress.gov...
"The transparency that Dr. Bucshon mentioned is important and, Mr. Griffith, the point you made about the benefit going to the patient actually raises a pretty serious question."
"There has got to be some flexibility."
"I am not opposed to having the FTC with some limited rulemaking authority in this space."
"I would like to be the one making the choice."